Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.
A committee of independent FDA vaccination advisors have been assessing the safety of the company's vaccine on Tuesday at a FDA Advisory Committee meeting.
The committee aims to decide whether or not it should recommend the Novavax vaccine for adults in the U.S. Following the meeting, the FDA will make a final authorization decision. The Novavax vaccine has already been authorized in several countries outside the U.S. It would be the fourth COVID-19 vaccine to receive authorization in the U.S.
Novavax is a biotechnology company that works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
See Also: Why Kiromic Biopharma Shares Are Skyrocketing Today
NVAX Price Action: Novavax shares have traded between $41.10 and $277.79 over a 52-week period.
The stock remained halted at press time, according to data from Benzinga Pro.
Photo: Maryland GovPics from Flickr.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga